The DOI matches its Crossref record; 283 of the 283 references it cites were found in a registry or an index.
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Open accessAbstract
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lu, T., Zhang, L., Zhu, W., Zhang, Y., Zhang, S., Wu, B., & Deng, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01529 · Cited by 7
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationAdvances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421
Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy
Wu, M., & Yang, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606134 · Cited by 2,285
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements
Mojica, F. J. M., D�ez-Villase�or, C., Garc�a-Mart�nez, J., & Soria, E. (2005) · Journal of Molecular Evolution · doi:10.1007/s00239-004-0046-3 · Cited by 2,042
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Identification of genes that are associated with DNA repeats in prokaryotes
Jansen, R., Embden, J. D. A. V., Gaastra, W., & Schouls, L. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02839.x · Cited by 1,802
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Bolotin, A., Quinquis, B., Sorokin, A., & Ehrlich, S. D. (2005) · Microbiology · doi:10.1099/mic.0.28048-0 · Cited by 1,558
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Self-citationInsight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Foroozandeh, P., & Aziz, A. A. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2728-6 · Cited by 1,377
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Extracellular vesicles for drug delivery.
Vader, P., Mol, E. A., Pasterkamp, G., & Schiffelers, R. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.006 · Cited by 1,319
RNA Interference: Biology, Mechanism, and Applications
Agrawal, N., Dasaradhi, P. V. N., Mohmmed, A., Malhotra, P., Bhatnagar, R. K., & Mukherjee, S. K. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.657-685.2003 · Cited by 1,305
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Phage Response to CRISPR-Encoded Resistance in Streptococcus thermophilus
Deveau, H., Barrangou, R., Garneau, J. E., Labonté, J., Fremaux, C., Boyaval, P., Romero, D. A., Horvath, P., & Moineau, S. (2008) · Journal of Bacteriology · doi:10.1128/jb.01412-07 · Cited by 1,213
Mesoporous silica nanoparticles in drug delivery and biomedical applications
Wang, Y., Zhao, Q., Han, N., Bai, L., Li, J., Liu, J., Che, E., Hu, L., Zhang, Q., Jiang, T., et al. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2014.09.014 · Cited by 1,192
Self-citationEnhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Synthesis of Copper Peroxide Nanodots for H2O2 Self-Supplying Chemodynamic Therapy
Lin, L.-S., Huang, T., Song, J., Ou, X.-Y., Wang, Z., Deng, H., Tian, R., Liu, Y., Wang, J.-F., Liu, Y., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03457 · Cited by 1,129
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Ash, C., Dubec, M., Donne, K., & Bashford, T. (2017) · Lasers in Medical Science · doi:10.1007/s10103-017-2317-4 · Cited by 1,040
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Current development of biodegradable polymeric materials for biomedical applications
Song, R., Murphy, M., Li, C., Ting, K., Soo, C., & Zheng, Z. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165440 · Cited by 915
Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
Mi, P. (2020) · Theranostics · doi:10.7150/thno.38069 · Cited by 830
Nano-niosomes as nanoscale drug delivery systems: An illustrated review
Moghassemi, S., & Hadjizadeh, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.015 · Cited by 797
Diversity, Activity, and Evolution of CRISPR Loci in Streptococcus thermophilus
Horvath, P., Romero, D. A., Coûté-Monvoisin, A.-C., Richards, M., Deveau, H., Moineau, S., Boyaval, P., Fremaux, C., & Barrangou, R. (2008) · Journal of Bacteriology · doi:10.1128/jb.01415-07 · Cited by 780
Metal–Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications
Sun, Y., Zheng, L., Yang, Y., Qian, X., Fu, T., Li, X., Yang, Z., Yan, H., Cui, C., & Tan, W. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00423-3 · Cited by 723
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701
Metal-organic frameworks for stimuli-responsive drug delivery
Wang, Y., Yan, J., Wen, N., Xiong, H., Cai, S., He, Q., Hu, Y., Peng, D., Liu, Z., & Liu, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119619 · Cited by 665
Self-citationGene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655
Self versus non-self discrimination during CRISPR RNA-directed immunity
Marraffini, L. A., & Sontheimer, E. J. (2010) · Nature · doi:10.1038/nature08703 · Cited by 637
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 619
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Self-citationCationic lipids, lipoplexes and intracellular delivery of genes
Wasungu, L., & Hoekstra, D. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.024 · Cited by 595
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 590
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Wang, Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0840-5 · Cited by 539
Self-citationAptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
Pi, F., Binzel, D. W., Lee, T. J., Li, Z., Sun, M., Rychahou, P., Li, H., Haque, F., Wang, S., Croce, C. M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0012-z · Cited by 494
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Quantum dots as a platform for nanoparticle drug delivery vehicle design
Probst, C. E., Zrazhevskiy, P., Bagalkot, V., & Gao, X. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.036 · Cited by 466
Chen, W., Meng, F., Cheng, R., & Zhong, Z. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.023 · Cited by 458
Piffoux, M., Silva, A. K. A., Wilhelm, C., Gazeau, F., & Tareste, D. (2018) · ACS Nano · doi:10.1021/acsnano.8b02053 · Cited by 456
Surface modification and chemical functionalization of carbon dots: a review
Yan, F., Jiang, Y., Sun, X., Bai, Z., Zhang, Y., & Zhou, X. (2018) · Microchimica Acta · doi:10.1007/s00604-018-2953-9 · Cited by 451
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Gan, R.-Y., Li, H.-B., Sui, Z.-Q., & Corke, H. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1231168 · Cited by 438
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
Carriers Break Barriers in Drug Delivery: Endocytosis and Endosomal Escape of Gene Delivery Vectors
Degors, I. M. S., Wang, C., Rehman, Z. U., & Zuhorn, I. S. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00177 · Cited by 424
Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.018 · Cited by 416
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review
Sun, Z., Song, C., Wang, C., Hu, Y., & Wu, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01020 · Cited by 413
Chung, J. E., Tan, S., Gao, S. J., Yongvongsoontorn, N., Kim, S. H., Lee, J. H., Choi, H. S., Yano, H., Zhuo, L., Kurisawa, M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.208 · Cited by 412
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
Wang, P., Zhang, L., Zheng, W., Cong, L., Guo, Z., Xie, Y., Wang, L., Tang, R., Feng, Q., Hamada, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708689 · Cited by 410
Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery
Battaglia, L., & Gallarate, M. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.673278 · Cited by 400
Liu, C., Wan, T., Wang, H., Zhang, S., Ping, Y., & Cheng, Y. (2019) · Science Advances · doi:10.1126/sciadv.aaw8922 · Cited by 396
Self-citationStimuli-Responsive Polymersomes for Biomedical Applications
Hu, X., Zhang, Y., Xie, Z., Jing, X., Bellotti, A., & Gu, Z. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01704 · Cited by 394
Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373
pH-Sensitive ZnO Quantum Dots–Doxorubicin Nanoparticles for Lung Cancer Targeted Drug Delivery
Cai, X., Luo, Y., Zhang, W., Du, D., & Lin, Y. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b04933 · Cited by 359
A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing
Chen, G., Abdeen, A. A., Wang, Y., Shahi, P. K., Robertson, S., Xie, R., Suzuki, M., Pattnaik, B. R., Saha, K., & Gong, S. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0539-2 · Cited by 358
Self-citationAbdelkader, H., Alani, A. W. G., & Alany, R. G. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838077 · Cited by 341
Surface chemistry of gold nanoparticles for health-related applications
Zhang, J., Mou, L., & Jiang, X. (2020) · Chemical Science · doi:10.1039/c9sc06497d · Cited by 333
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
CRISPR-Cas9 system: A new-fangled dawn in gene editing
Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R., Sinharoy, S., Acharya, K., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116636 · Cited by 323
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 315
Immunotherapeutic approaches for small-cell lung cancer
Iams, W. T., Porter, J., & Horn, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0316-z · Cited by 311
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Peptide Science · doi:10.1002/bip.10257 · Cited by 308
Liu, W., Yin, R., Xu, X., Zhang, L., Shi, W., & Cao, X. (2019) · Advanced Science · doi:10.1002/advs.201802373 · Cited by 304
Self-citationBioapplications of hyperbranched polymers
Wang, D., Zhao, T., Zhu, X., Yan, D., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00229f · Cited by 301
Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297
Self-citationMicelles structure development as a strategy to improve smart cancer therapy
Hanafy, N., El-Kemary, M., & Leporatti, S. (2018) · Cancers · doi:10.3390/cancers10070238 · Cited by 287
Pennisi, E. (2013) · Science · doi:10.1126/science.341.6148.833 · Cited by 287
Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
Wang, H.-X., Zuo, Z.-Q., Du, J.-Z., Wang, Y.-C., Sun, R., Cao, Z.-T., Ye, X.-D., Wang, J.-L., Leong, K. W., & Wang, J. (2016) · Nano Today · doi:10.1016/j.nantod.2016.04.008 · Cited by 285
Self-citationWang, H.-X., Song, Z., Lao, Y.-H., Xu, X., Gong, J., Cheng, D., Chakraborty, S., Park, J. S., Li, M., Huang, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712963115 · Cited by 277
Self-citationShukla, R., Chanda, N., Zambre, A., Upendran, A., Katti, K., Kulkarni, R. R., Nune, S. K., Casteel, S. W., Smith, C. J., Vimal, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121174109 · Cited by 273
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Near-infrared upconversion–activated CRISPR-Cas9 system: A remote-controlled gene editing platform
Pan, Y., Yang, J., Luan, X., Liu, X., Li, X., Yang, J., Huang, T., Sun, L., Wang, Y., Lin, Y., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav7199 · Cited by 271
Self-citationZhou, L., Mudianto, T., Ma, X., Riley, R., & Uppaluri, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1351 · Cited by 269
Sandiford, L., Phinikaridou, A., Protti, A., Meszaros, L. K., Cui, X., Yan, Y., Frodsham, G., Williamson, P. A., Gaddum, N., Botnar, R. M., et al. (2013) · ACS Nano · doi:10.1021/nn3046055 · Cited by 268
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
Wojnilowicz, M., Glab, A., Bertucci, A., Caruso, F., & Cavalieri, F. (2019) · ACS Nano · doi:10.1021/acsnano.8b05151 · Cited by 262
Mi, Y., Liu, Y., & Feng, S.-S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.022 · Cited by 261
Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems
Narmani, A., Rezvani, M., Farhood, B., Darkhor, P., Mohammadnejad, J., Amini, B., Refahi, S., & Abdi Goushbolagh, N. (2019) · Drug Development Research · doi:10.1002/ddr.21545 · Cited by 255
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Recent advances in "smart" delivery systems for extended drug release in cancer therapy
Kalaydina, R.-V., Bajwa, K., Qorri, B., DeCarlo, A., & Szewczuk, M. R. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s168053 · Cited by 249
Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
Liu, Y., Ran, R., Chen, J., Kuang, Q., Tang, J., Mei, L., Zhang, Q., Gao, H., Zhang, Z., & He, Q. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.031 · Cited by 246
Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, À., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 246
Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice
Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244
Ashley, C. E., Carnes, E. C., Epler, K. E., Padilla, D. P., Phillips, G. K., Castillo, R. E., Wilkinson, D. C., Wilkinson, B. S., Burgard, C. A., Kalinich, R. M., et al. (2012) · ACS Nano · doi:10.1021/nn204102q · Cited by 239
Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs
Gothwal, A., Khan, I., & Gupta, U. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1784-1 · Cited by 233
Engineering Biomimetic Platesomes for pH‐Responsive Drug Delivery and Enhanced Antitumor Activity
Liu, G., Zhao, X., Zhang, Y., Xu, J., Xu, J., Li, Y., Min, H., Shi, J., Zhao, Y., Wei, J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900795 · Cited by 233
Xu, G., Chhangawala, S., Cocco, E., Razavi, P., Cai, Y., Otto, J. E., Ferrando, L., Selenica, P., Ladewig, E., Chan, C., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0554-0 · Cited by 229
Cell-Type-Specific CRISPR/Cas9 Delivery by Biomimetic Metal Organic Frameworks
Alyami, M. Z., Alsaiari, S. K., Li, Y., Qutub, S. S., Aleisa, F. A., Sougrat, R., Merzaban, J. S., & Khashab, N. M. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11638 · Cited by 227
Michels, B. E., Mosa, M. H., Streibl, B. I., Zhan, T., Menche, C., Abou-El-Ardat, K., Darvishi, T., Członka, E., Wagner, S., Winter, J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.003 · Cited by 222
Zhen, S., Hua, L., Takahashi, Y., Narita, S., Liu, Y.-H., & Li, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.014 · Cited by 219
Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
Zhang, L., Wang, P., Feng, Q., Wang, N., Chen, Z., Huang, Y., Zheng, W., & Jiang, X. (2017) · NPG Asia Materials · doi:10.1038/am.2017.185 · Cited by 218
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Liang, C., Li, F., Wang, L., Zhang, Z.-K., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A. B., Liu, J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.015 · Cited by 216
Shi, Y., van der Meel, R., Theek, B., Oude Blenke, E., Pieters, E. H. E., Fens, M. H. A. M., Ehling, J., Schiffelers, R. M., Storm, G., van Nostrum, C. F., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b00929 · Cited by 214
Wang, P., Zhang, L., Xie, Y., Wang, N., Tang, R., Zheng, W., & Jiang, X. (2017) · Advanced Science · doi:10.1002/advs.201700175 · Cited by 214
Patil, M. L., Zhang, M., & Minko, T. (2011) · ACS Nano · doi:10.1021/nn102711d · Cited by 210
Deng, K., Hou, Z., Li, X., Li, C., Zhang, Y., Deng, X., Cheng, Z., & Lin, J. (2015) · Scientific Reports · doi:10.1038/srep07851 · Cited by 206
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 205
Ultrasensitive pH Triggered Charge/Size Dual-Rebound Gene Delivery System
Guan, X., Guo, Z., Lin, L., Chen, J., Tian, H., & Chen, X. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02536 · Cited by 201
Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy
Li, W., Liu, Z., Fontana, F., Ding, Y., Liu, D., Hirvonen, J. T., & Santos, H. A. (2018) · Advanced Materials · doi:10.1002/adma.201703740 · Cited by 200
Aptamer-functionalized liposomes for targeted cancer therapy
Moosavian, S. A., & Sahebkar, A. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.045 · Cited by 200
Porous Silicon Nanoparticles for Nanomedicine: Preparation and Biomedical Applications
Santos, H. A., Mäkilä, E., Airaksinen, A. J., Bimbo, L. M., & Hirvonen, J. (2014) · Nanomedicine · doi:10.2217/nnm.13.223 · Cited by 198
Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing
Chen, X., Chen, Y., Xin, H., Wan, T., & Ping, Y. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912220117 · Cited by 196
Influence of nanomedicine mechanical properties on tumor targeting delivery
Li, Z., Xiao, C., Yong, T., Li, Z., Gan, L., & Yang, X. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00575g · Cited by 196
Zhou, W., Cui, H., Ying, L., & Yu, X. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201806941 · Cited by 195
Liu, Q., Zhao, K., Wang, C., Zhang, Z., Zheng, C., Zhao, Y., Zheng, Y., Liu, C., An, Y., Shi, L., et al. (2019) · Advanced Science · doi:10.1002/advs.201801423 · Cited by 190
Self-citationModeling Breast Cancer Using CRISPR-Cas9–Mediated Engineering of Human Breast Organoids
Dekkers, J. F., Whittle, J. R., Vaillant, F., Chen, H.-R., Dawson, C., Liu, K., Geurts, M. H., Herold, M. J., Clevers, H., Lindeman, G. J., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz196 · Cited by 188
Rational designs of in vivo CRISPR-Cas delivery systems
Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 184
Aptamers and Their Applications in Nanomedicine
Sun, H., & Zu, Y. (2015) · Small · doi:10.1002/smll.201403073 · Cited by 180
Zhuang, J., Tan, J., Wu, C., Zhang, J., Liu, T., Fan, C., Li, J., & Zhang, Y. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa683 · Cited by 176
Functional Carbon Quantum Dots: A Versatile Platform for Chemosensing and Biosensing
Feng, H., & Qian, Z. (2018) · The Chemical Record · doi:10.1002/tcr.201700055 · Cited by 172
Deng, S., Li, X., Liu, S., Chen, J., Li, M., Chew, S. Y., Leong, K. W., & Cheng, D. (2020) · Science Advances · doi:10.1126/sciadv.abb4005 · Cited by 169
Pedro, S. N., Freire, M. G., Freire, C. S. R., & Silvestre, A. J. D. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1604680 · Cited by 167
A nanoparticle’s pathway into tumours
de Lázaro, I., & Mooney, D. J. (2020) · Nature Materials · doi:10.1038/s41563-020-0669-9 · Cited by 167
Recent Advances in Molecular Imaging with Gold Nanoparticles
Bouché, M., Hsu, J. C., Dong, Y. C., Kim, J., Taing, K., & Cormode, D. P. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00669 · Cited by 166
Han, J., Wang, Q., Zhang, Z., Gong, T., & Sun, X. (2014) · Small · doi:10.1002/smll.201301992 · Cited by 164
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163
Liu, Q., Wang, C., Zheng, Y., Zhao, Y., Wang, Y., Hao, J., Zhao, X., Yi, K., Shi, L., Kang, C., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120275 · Cited by 148
Self-citationControlled drug delivery systems for cancer based on mesoporous silica nanoparticles
Iturrioz-Rodríguez, N., Correa‐Duarte, M. A., & Fanárraga, M. L. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s198848 · Cited by 146
Synthesis and functionalization of hyperbranched polymers for targeted drug delivery
Kavand, A., Anton, N., Vandamme, T., Serra, C. A., & Chan‐Seng, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.019 · Cited by 143
Photoresponsive Drug/Gene Delivery Systems
Zhou, Y., Ye, H., Chen, Y., Zhu, R., & Yin, L. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00422 · Cited by 142
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics
Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 142
Anti‐MUC1 aptamer: A potential opportunity for cancer treatment
Nabavinia, M. S., Gholoobi, A., Charbgoo, F., Nabavinia, M., Ramezani, M., & Abnous, K. (2017) · Medicinal Research Reviews · doi:10.1002/med.21462 · Cited by 141
Zhang, B.-C., Luo, B.-Y., Zou, J., Wu, P., Jiang, J., Le, J., Zhao, R., Chen, L., & Shao, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c17660 · Cited by 141
Eş, İ., Gavahian, M., Martí-Quijal, F. J., Lorenzo, J. M., Khaneghah, A. M., Tsatsanis, C., Kampranis, S. C., & Barba, F. J. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.006 · Cited by 140
A Self-Assembled Platform Based on Branched DNA for sgRNA/Cas9/Antisense Delivery
Liu, J., Wu, T., Lu, X., Wu, X., Liu, S., Zhao, S., Xu, X., & Ding, B. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b09043 · Cited by 140
Self-citationRGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139
He, X., Ren, X., Peng, Y., Zhang, J., Ai, S., Liu, B., Xu, C., & Cheng, S. (2020) · Advanced Materials · doi:10.1002/adma.202000208 · Cited by 138
Lyu, Y., He, S., Li, J., Jiang, Y., Sun, H., Miao, Y., & Pu, K. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909264 · Cited by 136
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Self-citationLi, M., Xie, H., Liu, Y., Xia, C., Cun, X., Long, Y., Chen, X., Deng, M., Guo, R., Zhang, Z., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.019 · Cited by 129
Zhen, S., Takahashi, Y., Narita, S., Yang, Y., & Xu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14072 · Cited by 126
Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells
Carvalho, J., Paiva, A. A., Campello, M. P. C., Paulo, A., Mergny, J., Salgado, G. F. J., Queiroz, J. A., & Cruz, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-44388-9 · Cited by 126
Tu, K., Deng, H., Kong, L., Wang, Y., Yang, T., Hu, Q., Hu, M. Y., Yang, C., & Zhang, Z. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b23084 · Cited by 125
Self-citationSelf-assembled polymeric vesicles: Focus on polymersomes in cancer treatment
Araste, F., Aliabadi, A., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.027 · Cited by 121
Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis
Landgraf, M., Lahr, C. A., Kaur, I., Shafiee, A., Sánchez‐Herrero, A., Janowicz, P. W., Ravichandran, A., Howard, C. B., Cifuentes‐Rius, A., McGovern, J., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119791 · Cited by 119
Guo, P., Yang, J., Huang, J., Auguste, D. T., & Moses, M. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904697116 · Cited by 118
Wan, T. Y., Chen, Y., Pan, Q., Xu, X., Kang, Y., Gao, X., Huang, F., Wu, C., & Yuan, P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.015 · Cited by 118
Self-citationLiu, Y., Mei, L., Xu, C., Yu, Q., Shi, K., Zhang, L., Wang, Y., Zhang, Q., Gao, H., Zhang, Z., et al. (2015) · Theranostics · doi:10.7150/thno.13532 · Cited by 115
Self-citationCRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 112
Wang, Y., Shahi, P. K., Xie, R., Zhang, H., Abdeen, A. A., Yodsanit, N., Ma, Z., Saha, K., Pattnaik, B. R., & Gong, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.052 · Cited by 111
Self-citationEpidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Mitchell, R. A., Luwor, R. B., & Burgess, A. W. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.009 · Cited by 109
Jubair, L., Fallaha, S., & McMillan, N. A. J. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.012 · Cited by 108
Xu, Q., Zhang, Z., Zhao, L., Qin, Y., Cai, H., Geng, Z., Zhu, X., Zhang, W., Zhang, Y., Tan, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.033 · Cited by 108
Self-citationSox2 is required for tumor development and cancer cell proliferation in osteosarcoma
Maurizi, G., Verma, N., Gadi, A., Mansukhani, A., & Basilico, C. (2018) · Oncogene · doi:10.1038/s41388-018-0292-2 · Cited by 107
Ju, E., Li, T., da Silva, S. R., & Gao, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12335 · Cited by 107
Sharma, A. K., Prasher, P., Aljabali, A. A. A., Mishra, V. K., Gandhi, H., Kumar, S., Mutalik, S., Chellappan, D. K., Tambuwala, M. M., Dua, K., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00789-2 · Cited by 106
Chun-ling, Z., Song, X.-Y., Zhou, W., Yang, H., Wen, Y., & Wang, X. (2009) · Journal of Materials Chemistry · doi:10.1039/b907978e · Cited by 105
Hazafa, A., Mumtaz, M., Farooq, M. F., Bilal, S., Chaudhry, S. N., Firdous, M., Naeem, H., Ullah, M. O., Yameen, M., Mukhtiar, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118525 · Cited by 102
Lao, Y., Li, M., Gao, M. A., Shao, D., Chi, C., Huang, D., Chakraborty, S., Ho, T., Jiang, W., Wang, H., et al. (2018) · Advanced Science · doi:10.1002/advs.201700540 · Cited by 101
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 101
Zhao, F., Yin, H. Y., Zhang, Z., & Li, J. (2013) · Biomacromolecules · doi:10.1021/bm301718f · Cited by 100
Porous Inorganic Drug Delivery Systems—a Review
Sayed, E., Haj‐Ahmad, R., Ruparelia, K. C., Arshad, M. S., Chang, M., & Ahmad, Z. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-017-0740-2 · Cited by 100
Valency‐Controlled Framework Nucleic Acid Signal Amplifiers
Liu, Q., Ge, Z., Mao, X., Zhou, G., Zuo, X., Shen, J., Shi, J., Li, J., Wang, L., Chen, X., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802701 · Cited by 99
Tang, Q., Liu, J., Jiang, Y. Y., Zhang, M., Mao, L., & Wang, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17749 · Cited by 99
Deng, H., Tan, S., Gao, X., Zou, C., Xu, C., Tu, K., Song, Q., Fan, F., Huang, W., & Zhang, Z. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.004 · Cited by 98
Liu, T., Li, Z., Zhang, Q., Bernstein, K. D. A., Lozano‐Calderón, S. A., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13148 · Cited by 96
Gao, X., Jin, Z., Tan, X., Zhang, C., Zou, C., Zhang, W., Ding, J., Das, B. C., Severinov, K., Hitzeroth, I. I., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.045 · Cited by 96
Tsai, L., Hsieh, H., Lu, K.-Y., Wang, S.-Y., & Mi, F. (2015) · Nanomedicine · doi:10.2217/nnm.15.183 · Cited by 94
Roy, S., Zhu, D., Parak, W. J., & Feliu, N. (2020) · ACS Nano · doi:10.1021/acsnano.9b10219 · Cited by 94
Inorganic Porous Nanoparticles for Drug Delivery in Antitumoral Therapy
Parra‐Nieto, J., del Cid, M. A. G., de Cárcer, I. A., & Baeza, A. (2020) · Biotechnology Journal · doi:10.1002/biot.202000150 · Cited by 92
Mashreghi, M., Zamani, P., Moosavian, S. A., & Jaafari, M. R. (2020) · Nanoscale Research Letters · doi:10.1186/s11671-020-03334-9 · Cited by 89
Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli‐Responsive Vehicles
Cai, W., Luo, T., Mao, L., & Wang, M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005644 · Cited by 88
Chen, J., Li, X., Zhao, X., Wu, Q., Zhu, H., Mao, Z., & Gao, C. (2018) · Bioactive Materials · doi:10.1016/j.bioactmat.2018.05.003 · Cited by 87
Cimadamore, A., Cheng, M., Santoni, M., Antonio Lopez-beltran, B., Battelli, N., Massari, F., Galosi, A. B., Scarpelli, M., & Montironi, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00653 · Cited by 87
Wang, Y., Gao, B., Tan, P. Y., Handoko, Y. A., Sekar, K., Deivasigamani, A., Seshachalam, V. P., Ouyang, H., Shi, M., Xie, C., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802213rr · Cited by 87
Self-citationTumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Zhao, N., Qin, Y., Liu, H., & Cheng, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520617666170419143459 · Cited by 86
Cited by
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
The application of the CRISPR-Cas system in antibiotic resistance
Tao, S., Chen, H., Li, N., & Liang, W. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s370869 · Cited by 147
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Metadata
- Authors
- Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 176
- Pages
- 113891
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3185214580
- Cited by
- 289
- References
- 283
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.